CASE REPORT

Short stature and melanocytic nevi in a girl with ARID1B-related Coffin-Siris syndrome: a case report

Dong-Ying Tao1, Huan-Hong Niu1, Jing-Jing Zhang1, Hui-Qin Zhang1, Ming-Hua Zeng2 and Sheng-Quan Cheng1*

Abstract

Background: Coffin-Siris syndrome (CSS) is a rare autosomal dominant disorder characterized by intellectual disability, developmental delay, and characteristic facial features. Few patients with cutaneous phenotype in this rare syndrome have been reported.

Case presentation: Herein, we describe a 12-year-old Chinese girl diagnosed with CSS, who was referred to our hospital because of intellectual disability and short stature. Prominent characteristics of the cutaneous system were observed: (1) A congenital giant nevus from the left frontal and temporal regions to the entire left scalp; and (2) multiple melanocytic nevi on the face and trunk. Whole exome sequencing revealed a novel heterozygous variant in the ARID1B gene. Recombinant human growth hormone (rhGH) was given for short stature, and resulted in significantly improved height. No enlargement or malignant transformation of nevi occurred within 4 years of follow-up.

Conclusion: The symptoms in cutaneous system is noteworthy, which may be a neglected phenotype in CSS. The therapeutic response of growth hormone is effective in this patient and no tumor related signs were found.

Keywords: Coffin-Siris syndrome, Short stature, Congenital giant nevus, Case report

Background

Coffin-Siris syndrome (CSS) (OMIM#135,900) is a rare autosomal dominant syndrome. Its pathogenesis is related to SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling enzymes [1]. To date, mutations in one of the ten SWI/SNF subunits, ARID1A, ARID1B, SMARCA4, SMARBI, SMARCE1, ARID2, DPF2, SMARCC2, SOX11, and PHF6, have been demonstrated to cause CSS [2]. Approximately 60% of cases were caused by mutations in ARID1B [3].

CSS is defined by particular facial traits, developmental delay and mental retardation, and plasia or hypoplasia of the distal phalanx or nail of the fifth and additional digits [4]. Moreover, CSS patients frequently presented with multisystem damage such as cardiac malformations, gastrointestinal and endocrine abnormalities, and visual and hearing impairment [4, 5]. Short stature is a common symptom of CSS. However, details on growth hormone (GH) therapy is lacking. Abnormality in cutaneous system have been reported in only three CSS cases so far [6–8]. Among them, two were ARID1B-related cases and both presented with vitiligo together with numerous melanocytic nevi [6] or without [7]; and one was ARID2 deficient case, who presented with anomalous skin pigmentation [8]. Here, we report the clinical characteristics of a short girl re-diagnosed as having ARID1B-related CSS, with...
multiple nevi, and her response to recombinant human growth hormone (rhGH) treatment.

**Case presentation**

The patient was the second child of non-consanguineous Chinese parents born at full term. The parents were both healthy. Her birth weight was 2500 g (P50) and length was 49.0 cm (P3). At birth, a black nevus was observed on her left temporal region as well as on her forehead to the entire scalp on the left side, which was not enlarged subsequently. She could not sit until 9-month-old, and walk independently until 18-month-old. She began to speak the words “dada” and “mama” at 24-month-old and now she can say complete sentences in broken words. At 4 years, she was diagnosed with vitiligo because of asymptomatic multiple leukoplakias on her neck skin. At 7 years, she was diagnosed with attention deficit hyperactivity disorder due to learning difficulties and an intelligence test score of 70. She suffered epileptic attacks since the age of 9 years and presented with generalized tonic–clonic seizures. At the age of 10 years and 9 month, her height was 123 cm (< P3), with bone age at 8 years and 10 month by the Gruelich and Pyle standards. The GH peak on stimulation test was 3.17 ng/mL and insulin-like growth factor 1 level was 136 ng/mL (reference range: 117–771). Thus, she was diagnosed with GH deficiency and started rhGH therapy. The therapy had lasted for 12 months during which rhGH dosage was adjusted to keep within a therapeutic range of 0.12–0.15 mg/kg/day, and her height increased by 13 cm. Insulin-like growth factor-1 (IGF-1), blood glucose and thyroid function were followed up every 3 months during the treatment.

She was then referred to our hospital at 12 years due to mental retardation and short stature. Her height was 137 cm (< P3) and weight was 36.5 kg (P25- P50). On physical examination, distinct features of CSS were noticed (Fig. 1), including: (1) Coarse face, low hairline, bushy eyebrows, broad nasal bridge, high palate, small lower jaw and thick lower lip vermilion, and multiple nevi on the face and trunk; (2) a single transverse palmar crease in the right hand; and (3) dysplasia of the middle segment in the fifth finger showed by radiological examination. Giant nevus on the left scalp was first observed in such case. Laboratory examinations showed no abnormality in routine blood, liver and kidney function, myocardial enzyme, serum electrolytes, tumor marker, and thyroid function tests (supplementary table 1). Cranial magnetic resonance imaging (MRI) and pituitary MRI were normal. Whole exome and Sanger sequencing were performed on blood-extracted DNA from the patient and her father.

![Figure 1](image-url)
heterozygous ARID1B variant NM_001374828.1:c.3099delT (p.Phe1034Serfs*3) was identified, and regarded as pathogenic according to the American College of Medical Genetics guidelines [9]. Sanger sequencing confirmed that the variant was de novo (Fig. 2).

The patient was re-diagnosed as having ARID1B-related CSS. On demand of the family's request for cure of short stature, rhGH was administered for 14 months. The girl caught up with a height of 150 cm (P10). No enlargement or malignant transformation of the melanocytic nevi on the face and trunk was observed within 4 years of follow-up.

**Conclusion and discussions**

This paper reports for the first time that a congenital giant nevus was present in an ARID1B-related CSS case. This case can be explained by a novel heterozygous variant c.3099delT (p.Phe1034Serfs*3). The typical characteristics of facial, hand, little finger, skin, and genetic results promoted us to correct the clinical diagnosis of the affected girl.

Of note, about 80 patients with CSS syndrome due to ARID1B mutations have been reported [10]. Yet, multiple nevi and vitiligo were not recorded in OMIM. It is reasonable to recommend that these two phenotypes be considered as characteristics of CSS. Traditional and newly phenotypes of CSS are listed in Table 1.

At present, studies have found that approximately 96.0% of patients with ARID1B variant show a height of < −1 SD and a mean adult height of −1.8 SD. A few cases mentioned that height improved significantly after rhGH treatment [11], but without detailed description. The patient in this study benefited significantly from rhGH treatment, with height increased 28 cm within 3 years. Her response in height to the treatment is comparable to the GHD patients [12].

Researches in 3 CSS patients suffered from hepatoblastoma [13], schwannoma and meningioma [14], and palillary thyroid carcinoma [15]. For the sake of safety, according to the guidelines for the use of growth hormone [12], we have fully screened the patients except for the cases with tumor.

Congenital giant nevus and melanocytic nevi were very prominent in this case. Abnormalities in the Wnt signaling pathway have been demonstrated to be associated with mental retardation in CSS patients [16]. The Wnt signaling pathway interacts with Gnaq/Gnall and RAS, RAF, MEK, and ERK signaling pathways (downstream signaling molecules) to promote the proliferation and differentiation of melanin stem cells and stimulate development of congenital giant nevi [17]. Although nevi may be at risk of carcinogenesis, no CSS cases with melanoma have been reported. After the evaluation by dermatologists and oncologists, the giant nevus is likely to be benign. After years of follow-up, no enlargement or increase of nevus was found.

In conclusion, the symptoms in cutaneous system is noteworthy, which may be a neglected phenotype in CSS. The therapeutic response of growth hormone is effective in this patient and no tumor related signs were found.

| Table 1 Clinical phenotypes of the patient |
|-------------------------------------------|
| **Part of the body** | **Phenotype** | **OMIM** | **Customary to CSS** | **Ref** |
|------------------------|---------------|----------|------------------|-------|
| Neuro system | Developmental delay, mental retardation, seizure | ✓ | ✓ | ✓ [4] |
| Face | Coarse face, small chin, coppery filamentous hair, bushy eyebrows, wide nose tip | ✓ | ✓ | ✓ [4] |
| Skeletal | Dysplasia of the middle segment of the fifth finger | ✓ | ✓ | ✓ [4] |
| Stature | Short | ✓ | ✓ | ✓ [4] |
| Skin | Melanocytic nevi | — | — | ✓ [6] |
| Congenital giant nevus | — | — | — |
| Vitiligo | — | — | ✓ [6–8] |

—: Not recorded in OMIM, not customary to Coffin-Siris syndrome (CSS), and not reported in the public literature

✓: Reported in OMIM, customary to CSS, and reported in the public literature

CSS Coffin-Siris syndrome
Abbreviations

CSS: Coffin-Siris syndrome; GH: Growth hormone; rhGH: Recombinant human growth hormone; SWS/SNF: Switch/Sucrose Non-Fermentable; IGF-1: Insulin-like growth factor-1.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12887-022-03535-4.

Additional file 1. Serum electrolytes, tumor markers and thyroid function tests.

Acknowledgements

We are grateful to the patient who has given his informed consent for the publication of this case report.

Authors’ contributions

TDY was the patient’s doctor in charge, reviewed the literature, and drafted the manuscript; NHH reviewed the literature and contributed to manuscript drafting; CSQ was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.

Funding

No funding to declare.

Availability of data and materials

The datasets analyzed during the current study are under submission to NCBI ClinVar (The ClinVar assessment number: SCV002549918).

Declarations

Ethics approval and consent to participate

The patient’s parents provided written informed consent to exome sequencing and inclusion into the research study approved by the Giannina Gaslini Children’s Institute Ethics Committee.

Consent for publication

The parents gave their informed consents for their child’s personal or clinical details along with any identifying images to be published in this study. A copy of the signed, written informed consent for publication form is available for review by the editor.

Competing interests

All authors declare no disclosures relevant to the manuscript.

Author details

1 Department of Pediatrics, Xijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xiancheng District, Xian 710032, Shaanxi Province, China. 2 Medical Experiment and Training Center, Hanzhong Vocational and Technical College, Hanzhong 723002, Shaanxi Province, China.

Received: 7 April 2022 Accepted: 2 August 2022

Received online: 13 August 2022

References

1. Santen GW, Atten E, Vulto-van Silfhout AT, Pottinger C, van Bon BW, van Minderhout IJ, et al. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat. 2013;34:1519–28. https://doi.org/10.1002/humu.22394 (PMID: 23926868).
2. Vasilievou G, Vergarajuaregui S, Endele S, Popp B, Büttner C, Elizbi AB, et al. Mutations in the BAF-Complex Subunit DPF2 Are Associated with Coffin-Siris Syndrome. Am J Hum Genet. 2018;102:468–79. https://doi.org/10.1016/j.ajhg.2018.01.014 (PMID: 29429572).
3. Tsurusaki Y, Okamoto N, Ohashi H, Mizuno S, Matsumoto N, Makita Y, et al. Coffin-Siris syndrome is a SWI/SNF complex disorder. Clin Genet. 2014;85:548–54. https://doi.org/10.1111/cge.12225 (PMID: 2385551).